{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:31:23Z","timestamp":1793640683719,"version":"4.5.1"},"reference-count":12,"publisher":null,"issue":"8","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim<\/jats:italic>\n                    \u00a0\u00a0\u00a0\u00a0\u00a0 To study the effectiveness of nebulized surfactant therapy as a part of a multimodality treatment of severe and extremely severe COVID-19 viral pneumonia with concomitant cardiovascular diseases (CVDs).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Material and methods\u00a0<\/jats:italic>\n                    This retrospective controlled study analyzed a multimodality treatment of 38 patients with severe and extremely severe COVID-19 viral pneumonia and concomitant CVDs who were administered nebulized surfactant for correction of acute respiratory distress syndrome (ARDS). The control group consisted of 105 patients with severe and extremely severe novel coronavirus infection with concomitant CVDs who were not administered surfactant as a part of the multimodality therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    Administration of nebulized surfactant as a part of the multimodality treatment in patients with COVID-19 allowed alleviating the severity of respiratory insufficiency (\u0440&lt;0.001), which decreased the death rate of patients with severe and extremely severe COVID-19 and undoubtedly demonstrated the effectiveness of this medicine. The timely multimodality therapy, including nebulized surfactant, improves the course of the disease. Thus, the absence of a possibility for administering nebulized surfactant for more than 4 days was associated with fatal outcomes (\u0440=0.045).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    \u00a0\u00a0\u00a0\u00a0\u00a0 Administration of nebulized surfactant as a part of the multimodality treatment of severe and extremely severe COVID-19 and concomitant CVDs increases the survival (\u0440&lt;0.001) and reduces the mortality by 46\u200a%. The risk factors of an unfavorable outcome of this disease include an age older than 65 (\u0440=0.020), a positive polymerase chain reaction test (\u0440=0.037), a ferritin concentration at baseline &gt;600 mg\u200a\/ml (\u0440&lt;0.001), and a surfactant treatment duration &lt; 4 days (\u0440=0.045). Further study of the efficacy of nebulized surfactants as a part of the multimodality therapy is required and should include randomized clinical trials with a large number of patients and the development of distinct criteria for the treatment of ARDS.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>\u00a0<\/jats:italic>\n                  <\/jats:p>","DOI":"10.18087\/cardio.2022.8.n1815","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:39:39Z","timestamp":1662464379000},"page":"27-32","source":"Crossref","is-referenced-by-count":1,"title":["The use of an Inhaled Surfactant in Patients With Severe and Extremely Severe new Coronavirus Infection COVID-19 With Concomitant Cardiovascular Pathology"],"prefix":"10.68900","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1975-5521","authenticated-orcid":true,"given":"N. A.","family":"Trofimov","sequence":"first","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary;\r\nChuvash Republic Cardiological Dispensary, Cheboksary;\r\nInstitute for Advanced Medical Education, Cheboksary;\r\nFederal Center for Traumatology, Orthopedics, and Arthroplasty, Cheboksary;\r\nPrivolzhsky Research Medical University, Nizhny Novgorod"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2788-8762","authenticated-orcid":true,"given":"V. E.","family":"Babokin","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary;\r\nChuvash Republic Cardiological Dispensary, Cheboksary;\r\nInstitute for Advanced Medical Education, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. V.","family":"Dubova","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary;\r\nChuvash Republic Cardiological Dispensary, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. V.","family":"Koshelkova","sequence":"additional","affiliation":[{"name":"Chuvash Republic Cardiological Dispensary, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. V.","family":"Dimitrieva","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary;\r\nChuvash Republic Cardiological Dispensary, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Rodionov","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary;\r\nChuvash Republic Cardiological Dispensary, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. N.","family":"Abizov","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. V.","family":"Oreshnikov","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Anurov","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Zamlikhanova","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6662-2900","authenticated-orcid":true,"given":"Yu. A.","family":"Igonin","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. E.","family":"Gordeeva","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary;\r\nChuvash Republic Cardiological Dispensary, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. V.","family":"Surkova","sequence":"additional","affiliation":[{"name":"I.N. Uljyanov Chuvash State University, Cheboksary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5605-0128","authenticated-orcid":true,"given":"V. O.","family":"Nikolsky","sequence":"additional","affiliation":[{"name":"Nizhny Novgorod Regional Clinical Antituberculosis Dispensary, Nizhny Novgorod"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bautin A. E., Aptekar V. V., Lapshin K. B., etc. An exogenous surfactant in the complex treatment of severe pneumonia caused by the SARS-CoV-2 virus. Translational medicine. 2020; 7 (6): 55-64. DOI: 10.18705\/2311-4495-2020-7-6-55-64.","DOI":"10.18705\/2311-4495-2020-7-6-55-64"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ashbaugh D.G., Bigelow D.B., Petty T.L., Levine B.E. Acute respiratory distress in adults. Lancet. 1967;290(7511):319-23. DOI: 10.1016\/S0140 6736(67)90168-7.","DOI":"10.1016\/S0140-6736(67)90168-7"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Rosenberg O. A. Preparations of pulmonary surfactant and surfactant therapy of ARDS in the conditions of surgical resuscitation (literature review). Creative surgery and oncology. 2019;9(1):50\u201365. https:\/\/doi.org\/10.24060\/2076-3093-2019-9-1-50-65","DOI":"10.24060\/2076-3093-2019-9-1-50-65"},{"key":"ref4","unstructured":"Zilber A. P. Acute pulmonary injury syndrome. In: Zilber A. P. Etudes of respiratory medicine. Moscow: MEDpress-inform; 2007. pp. 478-5."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Thompson B. T., Ferguson N. D., Caldwell E., Fan E., Camporota L., Slutsky A. S. Acute respiratory distress syndrome: Berlin definition. JAMA. 2012;307(23):2526\u201333. DOI: 10.1001\/jama.2012.5669.","DOI":"10.1001\/jama.2012.5669"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180 (7): 934\u2013943.","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in Metropolitan Detroit. JAMA Netw Open. 2020; 3 (6): e2012270.","DOI":"10.1001\/jamanetworkopen.2020.12270"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Chand S, Kapoor S, Orsi D, et al. COVID-19- associated critical illness-report of the first 300 patients admitted to intensive care units at a New York City Medical Center. J Intensive Care Med. 2020; 35 (10): 963-970.","DOI":"10.1177\/0885066620946692"},{"key":"ref9","unstructured":"Bautin A. E., Osovskikh V. V., Khubulava G. G., etc. Multicenter clinical trials of surfactant-BL for the treatment of adult respiratory distress syndrome. Clinical trials of medicines in Russia. 2002; 2: 18\u201323,"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bautin A, Khubulava G, Kozlov I, et al. Surfactant therapy for patients with ARDS after cardiac surgery. J Liposome Res. 2006; 16: 265\u2013272","DOI":"10.1080\/08982100600850997"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Zhang H, Zhou P, Wei Y, et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann Intern Med. 2020; 172 (9): 629\u2013632.","DOI":"10.7326\/M20-0533"},{"key":"ref12","unstructured":"Guidelines of the all-russian public organization \u201cFederation ofanesthesiologists and reanimatologists\u201d for treatment ofinfluenza A\/H1N1\/2009. Vestnik anesteziologii i reanimatologii Bulletin of Anesthesiology and Reanimatology. 2011; (1): 41\u201347. In Russian [Methodological recommendations for the treatment of influenza A\/H1N1\/2009 of the All-Russian Public Organization \"Federation of Anesthesiologists and Resuscitators\". Bulletin of Anesthesiology and Resuscitation. 2011; 8 (1): 41\u201347."}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1815\/1261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:21Z","timestamp":1793639781000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":12,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,30]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2022.8.n1815","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}